Cisplatin, etoposide, and vincristine combination chemotherapy in the treatment of non-small cell lung cancer.

A. Watanabe, S. Ichiyama, K. Shimokata, E. Nagura, H. Saito, H. Saka, F. Nomura, S. Sakai, H. Saito

研究成果: ジャーナルへの寄稿学術論文査読

抄録

Thirty patients with previously untreated, inoperable non-small cell lung cancer (NSCLC) were treated with cisplatin, etoposide and vincristine. Among twenty-nine evaluable patients, eight patients achieved partial response and the overall response rate was 28%. No patient achieved a complete response. The median survival time was 51 weeks. Myelosuppression was the dose-limiting toxicity. Four patients had a leukocyte nadir of less than 1000/mm3, and one died from severe myelosuppression and sepsis. The other toxicities were nausea/vomiting, peripheral neuropathy, and alopecia. We conclude that cisplatin, etoposide, and vincristine combination chemotherapy offers moderate activity for inoperable non-small cell lung cancer.

本文言語英語
ページ(範囲)41-46
ページ数6
ジャーナルNagoya journal of medical science
55
1-4
出版ステータス出版済み - 03-1993
外部発表はい

All Science Journal Classification (ASJC) codes

  • 医学一般

フィンガープリント

「Cisplatin, etoposide, and vincristine combination chemotherapy in the treatment of non-small cell lung cancer.」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル